David Planchard, MD, PhD, Gustave Roussy Institute of Oncology

home / authors / david-planchard-md-phd-gustave-roussy-institute-of-oncology

Articles

David Planchard, MD, PhD,

Dr. Planchard on the Benefit of Sunvozertinib in EGFR Exon 20–Mutated NSCLC

David Planchard, MD, PhD, Gustave Roussy Institute of Oncology
September 2nd 2022

David Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).

Read More

Paradigm Shift for Early EGFR+ NSCLC

Paradigm Shift for Early EGFR+ NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Practical Implications of ADAURA in NSCLC

Practical Implications of ADAURA in NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Unprecedented Results from ADAURA

Unprecedented Results from ADAURA

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Adjuvant Approaches in EGFR+ NSCLC

Adjuvant Approaches in EGFR+ NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Standard of Care for EGFR+ ES-NSCLC

Standard of Care for EGFR+ ES-NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Testing for EGFR in NSCLC Worldwide

Testing for EGFR in NSCLC Worldwide

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Molecular Testing in Early-Stage NSCLC

Molecular Testing in Early-Stage NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Determining Resectability in ES-NSCLC

Determining Resectability in ES-NSCLC

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Clinical Evaluation of ES-NSCLC in Japan

Clinical Evaluation of ES-NSCLC in Japan

Masahiro Tsuboi, MD, National Cancer Center Hospital East;David Planchard, MD, PhD, Gustave Roussy Institute of Oncology;Maurice Perol, MD, Léon Bérard Cancer Center
October 20th 2020

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need